Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased
Technology for modulating autoimmunity expands intellectual property portfolio
Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes
Corporate and Clinical Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes
Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial
Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial
Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems
Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Designed and Secured by Barsec